About us
About us
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Report adverse event
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
About us
About us
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Report adverse event
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
Circulars and admission document
REGISTER FOR EMAIL ALERTS
Circular 29.06.21
PDF
Circular – Form of Proxy 29.06.21
PDF
Amryt Notice of General Meeting 29.06.21
PDF
GM Proxy Form 29.06.21
PDF
Articles of Association of Amryt Pharma PLC. July 2020 (red-lined)
PDF
Amryt Notice of Annual General Meeting 30.06.20
PDF
Amryt AGM Proxy Form 30.06.20
PDF
Amryt Equity Incentive Plan
PDF
Amryt Equity Incentive Plan: Sub-plan for US participants
PDF
Admission Document 27.08.2019
PDF
Restructuring Support Agreement PART I
PDF
Restructuring Support Agreement PART II
PDF
Aegerion – Plan Funding Agreement PART I
PDF
Aegerion – Plan Funding Agreement PART II
PDF
Grant Thornton Consent Letter
PDF
Stiftung Signed Undertaking
PDF
DIP Credit Agreement
PDF
Cooley – Patent Report
PDF
Joe Wiley – Signed Undertaking
PDF
Rory Nealon – Signed Undertaking
PDF
Shore Capital QFBS Report
PDF
Shore Capital Consent Letter
PDF
Ray Stafford – Signed Undertaking
PDF
Aegerion Patent Report
PDF
Secured Credit Facility
PDF
Aegerion – Contingent Value Rights Deed Poll
PDF
Backstop Subscription Agreement
PDF
Convertible Notes
PDF
Registration Rights Agreement
PDF
New Amryt – Articles
PDF
Aegerion Consent Letter
PDF
Aegerion Report on QFBS
PDF
Haug Partners Consent Letter
PDF
New Warrant Instrument
PDF
MTS QFBS Report
PDF
MTS Consent Letter
PDF
Aegerion – Deloitte Accountant Report
PDF
Amryt Pharma Plc Consent Letter
PDF
Davy Signed Consent Letter
PDF
Aegerion Constitutional Documents
PDF
Court Meeting Proxy
PDF
General Meeting Proxy
PDF
Amryt Notice of Annual General Meeting 10.07.2019
PDF
Amryt Notice of Annual General Meeting 05.06.2018
PDF
Amryt AGM Proxy Form 05.06.2018
PDF
Amryt Proxy Form October 2017
PDF
Amryt Circular October 2017
PDF
Amryt Notice of Annual General Meeting 25.05.2017
PDF
Amryt AGM Proxy Form 25.05.17
PDF
Admission Document May 2017
PDF
Admission Document April 2016
PDF
Fastnet Notice of Annual General Meeting 30.09.2015
PDF
Fastnet Circular 28.08.2015
PDF
Fastnet GM Proxy Form 28.08.15
PDF
Notice of Annual General Meeting 07.07.2016
PDF
Amryt Pharma has been acquired by Chiesi Farmaceutici S.p.A.
View the press release to learn more
.
CLOSE